Loading stock data…
MDXG
$3.67-0.05 (-1.21%)
Market OpenUpdated 3:00 PM EDT
MiMedx Group, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
MiMedx Group, Inc. in the Healthcare sector is trading at $3.67. Wall Street consensus targets $6.50 (6 analysts), implying a +77.4% move over the next 12 months. The stock is currently near its 52-week low of $3.03, remaining 34.4% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +77.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $58.99M↓ | $118.09M↑ | $113.72M↑ | $98.61M↑ | $88.20M |
| Gross Profit | $41.62M↓ | $99.04M↑ | $95.01M↑ | $79.92M↑ | $71.65M |
| Operating Income | -$16.05M↓ | $21.08M↓ | $22.19M↑ | $12.37M↑ | $8.25M |
| Net Income | -$10.86M↓ | $15.19M↓ | $16.75M↑ | $9.62M↑ | $7.02M |
Peer Comparison
JNJUNHPFE
Fundamentals
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PU...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
12.64%
Volume
Today's trading volume
584,953
Recent News
How The MiMedx Group (MDXG) Story Is Shifting As Analysts Rework Price Targets
Recent Street research on MiMedx Group has centered on trimming price targets by US$1 to US$5 at a time, as analysts recheck their assumptions. Those smaller step downs, whether bullish or bearish, line up with commentary that suggests many analysts are fine tuning their views on profitability and execution rather than completely rethinking the stock. As you read on, you will see how to track these price target moves and what they might signal for the evolving narrative around MiMedx...
Is the Options Market Predicting a Spike in MiMedx Group Stock?
Investors need to pay close attention to MDXG stock based on the movements in the options market lately.
Some May Be Optimistic About MiMedx Group's (NASDAQ:MDXG) Earnings
MiMedx Group, Inc.'s ( NASDAQ:MDXG ) stock was strong despite it releasing a soft earnings report last week. Our...
How Reimbursement Shifts Are Rewriting The MiMedx Group (MDXG) Investment Narrative
MiMedx Group is back in focus after analysts trimmed fair value estimates, with one key model now pointing to a reduced price target range that includes a shift from US$8.20 to US$6.50 per share. That change sits alongside broader research that highlights both pressure from reimbursement questions and specific factors that some analysts still see as supportive for the chronic wound care business over time. Read on to see what is driving the evolving narrative and how you can track it as new...
MiMedx Group, Inc. (NASDAQ:MDXG) Analysts Are Cutting Their Estimates: Here's What You Need To Know
It's shaping up to be a tough period for MiMedx Group, Inc. ( NASDAQ:MDXG ), which a week ago released some...